trans-4-{[(phenylmethoxy)carbonylamino]methyl}cyclohexanecarboxylic acid | 27687-12-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: trans-4-{[(phenylmethoxy)carbonylamino]methyl}cyclohexanecarboxylic acid
• 英文别名: (1r,4r)-4-({[(benzyloxy)carbonyl]amino}methyl)cyclohexane-1-carboxylic acid；trans-4-({[(benzyloxy)carbonyl]amino}-methyl)cyclohexanecarboxylic acid；trans-4-({[(benzyloxy)carbonyl]amino}methyl)cyclohexanecarboxylic acid；(trans)-4-((benzyloxycarbonylamino)methyl)cyclohexanecarboxylic acid；N-benzyloxycarbonyl-trans-4-(aminomethyl)cyclohexanecarboxylic acid；trans-4-(N-benzyloxycarbonyl-aminomethyl)cyclohexanecarboxylic acid
• CAS: 27687-12-3
• 化学式: C₁₆H₂₁NO₄
• 分子量: 291.347
• InChiKey: BTKCKOMQQMNUJB-MQMHXKEQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  21.0
• 可旋转键数：
  5.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.63
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  trans-4-{[(phenylmethoxy)carbonylamino]methyl}cyclohexanecarboxylic acid 在 palladium on activated charcoal 氯化亚砜 、 氢气 、 溶剂黄146 、 三乙胺 作用下， 生成 cetraxate
  参考文献：
  名称：

  抗纤溶酶药物的药物化学研究。4.反式-4-氨基甲基环己烷羧酸的化学修饰及其对抗纤溶酶活性的影响。

  摘要：

  DOI：

  10.1021/jm00273a011
• 作为产物：
  描述：

  methyl (1r,4r)-4-((((benzyloxy)carbonyl)amino)methyl)cyclohexane-1-carboxylate 在 sodium hydroxide 、 水 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 trans-4-{[(phenylmethoxy)carbonylamino]methyl}cyclohexanecarboxylic acid
  参考文献：
  名称：

  WO2007/87256

  摘要：

  公开号：

文献信息

• [EN] TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER<br/>[FR] PRODUITS RADIOPHARMACEUTIQUES CIBLÉS POUR LE DIAGNOSTIC ET LE TRAITEMENT DU CANCER DE LA PROSTATE
  申请人：BAYER AS

  公开号：WO2021013978A1

  公开（公告）日：2021-01-28

  A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.

  通用式(I)的化合物：其中：n为1、2或3；R1、R2、R3和R4独立地代表OH或Q；Q代表从群组中选择的组织靶向基团，或其立体异构体、水合物、溶剂合物、盐或其混合物，制备所述化合物的方法，用于制备所述化合物的中间化合物，包含所述化合物的药物组合物和组合物，以及用于制造用于治疗或预防疾病的药物组合物的所述化合物的用途，特别是软组织疾病的治疗或预防，作为唯一药剂或与其他活性成分结合使用。
• Fused purine derivatives
  申请人：——

  公开号：US20030176698A1

  公开（公告）日：2003-09-18

  A condensed purine derivative represented by Formula (I): 1 wherein X—Y—Z represents R 1 N—C═O or N═C—W, R 2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted alicyclic heterocyclic group or the like, n represents an integer of from 0 to 3, V 1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, V 2 represents a substituted lower alkyl group or a substituted or unsubstituted aromatic heterocyclic group, and when V 1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and for example, X—Y—Z represents R 1a N—C═O and R 2 represents a substituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted alicyclic heterocyclic group, a halogen atom, a lower alkylthio group, —NR 7 R 8 , —CO 2 H, a lower alkoxycarbonyl group, —COHal, —CONR 9 R 10 or —CHO, V 2 may represent a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group; or a pharmacologically acceptable salt thereof.

  一个由公式(I)表示的浓缩嘌呤衍生物：1 其中，X—Y—Z代表R1N—C═O或N═C—W，R2代表氢原子、取代或未取代的低级烷基团、取代或未取代的芳烷基团、取代或未取代的芳基团、取代或未取代的芳香杂环团、取代或未取代的脂肪杂环团等，n代表从0到3的整数，V1代表氢原子、取代或未取代的低级烷基团、取代或未取代的芳烷基团、取代或未取代的芳基团或取代或未取代的芳香杂环团，V2代表取代的低级烷基团或取代或未取代的芳香杂环团，并且当V1代表氢原子、低级烷基团、取代或未取代的芳烷基团或取代或未取代的芳基团时，例如，X—Y—Z代表R1aN—C═O并且R2代表取代的低级烷基团、取代或未取代的芳烷基团、取代或未取代的脂肪杂环团、卤素原子、低级烷基亚硫酰基团、—NR7R8、—CO2H、低级烷氧羰基团、—COHal、—CONR9R10或—CHO，V2可以代表低级烷基团、取代或未取代的芳烷基团或取代或未取代的芳基团；或其药理可接受的盐。
• Development of Selective Inhibitors against Plasma Kallikrein.
  作者：Naoki TENO、Keiko WANAKA、Yoshio OKADA、Yuko TSUDA、Utako OKAMOTO、Akiko HIJIKATA-OKUNOMIYA、Taketoshi NAITO、Shosuke OKAMOTO

  DOI：10.1248/cpb.39.2930

  日期：——

  Specific plasma kallikrein inhibitors were disigned and synthesized and their structure-activity relationship was studied. trans-4-Aminomethylcyclohexanecarbonyl(Tra)-lysyl-4-ethoxycarbonylanilide inhibited plasma kallikrein and plasmin with IC50 values of 23 and 210 μM, respectively, indicating that this compound is fairly specific to plasma kallikrein. Tra-arginyl-4-ethoxycarbonylanilide inhibited plasma kallikrein and plasmin with IC50 values of 16 and 480 μM, respectively. Tra-homoarginyl-4-carboxyanilide inhibited plasma kallikrein and plasmin with IC50 values of 14 μM and 1 mM, respectively. Finally, Tra-Arg(Mts)-4-acetylanilide (ACA) exhibited potent and seletive inhibitory activity against plasma kallikrein (IC50 value for plasma kallikrein : 2 μM and for plasmin : 42 μM).

  特异性血浆激肽释放酶抑制剂被设计并合成，其结构-活性关系得到研究。trans-4-氨基甲基环己烷羰基（Tra）-赖氨酰-4-乙氧基羰基苯胺对血浆激肽释放酶和纤溶酶的IC50值分别为23和210微摩尔，说明该化合物对血浆激肽释放酶具有相当高的特异性。Tra-精氨酰-4-乙氧基羰基苯胺对血浆激肽释放酶和纤溶酶的IC50值分别为16和480微摩尔。Tra-高精氨酰-4-羧基苯胺对血浆激肽释放酶和纤溶酶的IC50值分别为14微摩尔和1毫摩尔。最后，Tra-Arg(Mts)-4-乙酰苯胺（ACA）显示出对血浆激肽释放酶的强效且选择性的抑制活性（血浆激肽释放酶的IC50值为2微摩尔，纤溶酶的IC50值为42微摩尔）。
• Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
  申请人：Buck A. Elizabeth

  公开号：US20070280928A1

  公开（公告）日：2007-12-06

  The present invention provides a method for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein the agent is an mTOR inhibitor, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein said agent is an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. The present invention also provides a pharmaceutical composition comprising an EGFR kinase inhibitor and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing the methods of this invention is the compound erlotinib HCl (also known as TARCEVA®).

  本发明提供了一种治疗患者体内NSCL、胰腺、结肠或乳腺癌肿瘤或肿瘤转移的方法，包括向患者同时或顺序给予治疗有效量的EGFR激酶抑制剂和一种使肿瘤细胞对EGFR激酶抑制剂产生敏感性的药物的组合，其中该药物是mTOR抑制剂，可以附加其他药物或治疗，如其他抗癌药物或放射治疗。本发明还提供了一种治疗患者体内肿瘤或肿瘤转移的方法，包括向患者同时或顺序给予治疗有效量的EGFR激酶抑制剂和一种使肿瘤细胞对EGFR激酶抑制剂产生敏感性的药物的组合，其中该药物是一种能够结合并直接抑制mTORC1和mTORC2激酶的mTOR抑制剂。本发明还提供了一种制药组合物，包括一种能够结合并直接抑制mTORC1和mTORC2激酶的EGFR激酶抑制剂和mTOR抑制剂，以及一种药用载体。本发明中可用于实施该方法的EGFR激酶抑制剂的首选示例是化合物厄洛替尼盐酸盐（也称为TARCEVA®）。
• [EN] 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS<br/>[FR] COMPOSÉS DE 8-MÉTHYL-1-PHÉNYL-IMIDAZOL[1,5-A]PYRAZINE
  申请人：ORGANON NV

  公开号：WO2011095556A1

  公开（公告）日：2011-08-11

  The present invention provides 8-methyl-1 -phenyl-imidazo[1,5-a]pyrazine derivatives according to formula I or pharmaceutically acceptable salts thereof. The compounds of the current invention show inhibitory activity against Lck and can be used for the treatment of Lck-mediated diseases or Lck-mediated conditions such as inflammatory disorders.

  本发明提供了根据式I或其药学上可接受的盐制备的8-甲基-1-苯基-咪唑并[1,5-a]吡嗪衍生物。本发明的化合物显示对Lck的抑制活性，可用于治疗由Lck介导的疾病或Lck介导的炎症性疾病。